Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.72 |
| ▸ | HPGD | P15428 | 7/20 | 0.72 |
| ▸ | NPC1 | O15118 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.72 |
| ▸ | TP53 | P04637 | 4/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.72 |
| ▸ | RELA | Q04206 | 3/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | GLA | P06280 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | F2 | P00734 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.61 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4052772 | 0.87 | NPC1 (0.69) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12639231 | 0.86 | RAB9A (0.74) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4051577 | 0.86 | SMN1; SMN2 (0.74) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4059683 | 0.86 | NPC1 (0.65) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4052671 | 0.84 | NPC1 (0.62) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL376001 | 0.84 | ALDH1A1 (0.64) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4054520 | 0.83 | SMN1; SMN2 (0.74) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4053543 | 0.83 | NPC1 (0.65) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1199992 | 0.83 | PTPN2 (0.68) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL27520950 | 0.82 | ALDH1A1 (0.64) | ALDH1A1HPGDNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-4554683-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | Lantern Pharma Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2024-07-25 | — | — | US | disclosed |
| WO-2024016014-A2 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | THE UNIVERSITY OF HOUSTON SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008020180-A2 | METHODS OF INCREASING THE SENSITIVITY OF CANCER CELLS TO DNA DAMAGE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-02-21 | — | — | WO | disclosed |
| EP-1684736-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | Kudos Pharmaceuticals Limited (GB) | 2006-08-02 | — | — | EP | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
| WO-2005053662-A1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARMACEUTICALS LIMITED (GB) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | ALDH1A1 1781/4885HPGD 1833/4885NPC1 4253/4885 |
| US-20090012293-A1 | USE OF ARYL CHLORIDES IN PALLADIUM-CATALYZED C-H BOND FUNCTIONALIZATION | DBH, DDT, CYCS | ALDH1A1 117/4885HPGD 1702/4885NPC1 1565/4885 |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | ALDH1A1 349/4885HPGD 1350/4885NPC1 3786/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | ALDH1A1 1466/4885HPGD 1722/4885NPC1 3852/4885 |
| US-20240245643-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | ALDH1A1 747/4885HPGD 325/4885NPC1 4490/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | ALDH1A1 744/4885HPGD 359/4885NPC1 4486/4885 |
| US-20230255906-A1 | Targeting Serpin B9 in Cancer | SERPINB10, SERPINB8, SERPINE1 | ALDH1A1 3233/4885HPGD 1255/4885NPC1 1048/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | ALDH1A1 729/4885HPGD 313/4885NPC1 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.